M
Mary Jean Stempien
Publications - 5
Citations - 444
Mary Jean Stempien is an academic researcher. The author has contributed to research in topics: Levodopa-induced dyskinesia & Dyskinesia. The author has an hindex of 4, co-authored 5 publications receiving 366 citations.
Papers
More filters
Journal ArticleDOI
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.
Rajesh Pahwa,Caroline M. Tanner,Caroline M. Tanner,Robert A. Hauser,Stuart Isaacson,Paul A. Nausieda,Daniel D. Truong,Pinky Agarwal,Keith L. Hull,Kelly E. Lyons,Reed Johnson,Mary Jean Stempien +11 more
TL;DR: This is the first demonstration of an oral treatment reducing both LID and OFF time in patients with PD with dyskinesia, and may be an effective treatment for LID.
Journal ArticleDOI
Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study)
Rajesh Pahwa,Caroline M. Tanner,Robert A. Hauser,Kapil D. Sethi,Stuart Isaacson,Daniel D. Truong,Lynn K. Struck,April E. Ruby,Natalie McClure,Gregory T. Went,Mary Jean Stempien +10 more
TL;DR: ADS‐5102 was generally well tolerated and resulted in significant and dose‐dependent improvements in dyskinesia in PD patients.
Journal ArticleDOI
Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
Wolfgang H. Oertel,Karla Eggert,Rajesh Pahwa,Caroline M. Tanner,Robert A. Hauser,Claudia Trenkwalder,Reinhard Ehret,Jean-Philippe Azulay,Stuart Isaacson,Larissa Felt,Mary Jean Stempien +10 more
TL;DR: The treatment of levodopa‐induced dyskinesia in Parkinson's disease is an unmet need with no approved drug therapy.
Journal ArticleDOI
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study.
Robert A. Hauser,Rajesh Pahwa,Caroline M. Tanner,Wolfgang H. Oertel,Stuart Isaacson,Reed Johnson,Larissa Felt,Mary Jean Stempien +7 more
TL;DR: ADS-5102 was generally well tolerated in all groups, including DBS patients, and the safety profile was consistent with previous controlled studies.
Journal Article
Safety and Efficacy Study of ADS-5102 (Amantadine HCl) Extended Release Capsules in Levodopa-Induced Dyskinesia (EASED Study) (P4.053)
Rajesh Pahwa,Caroline M. Tanner,Robert A. Hauser,Kapil D. Sethi,Stuart Isaacson,Daniel D. Truong,Lynn K. Struck,Mary Jean Stempien,Natalie McClure,Greg Went +9 more
TL;DR: ADS-5102 in once nightly doses up to 420 mg was generally well tolerated and resulted in significant and dose-dependent improvements in Parkinson’s disease LID.